Sign In
Buy ARFXF
$0.102
+0 (+0%)
At Close: Jan 27, 2023
ProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus
07:30am, Thursday, 03'rd Jun 2021
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer
07:30am, Thursday, 27'th May 2021
TORONTO, and CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody thera
ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
08:30am, Friday, 21'st May 2021
PMN310 potential best in class antibody candidate for treatment of Alzheimer's disease PMN310 potential best in class antibody candidate for treatment of Alzheimer's disease
ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors
06:30am, Wednesday, 19'th May 2021
TORONTO and CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody thera
ProMIS Neurosciences Announces First Quarter 2021 Results
07:00am, Friday, 14'th May 2021
TORONTO and CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and
ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
06:30am, Wednesday, 12'th May 2021
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody thera
ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
10:44am, Monday, 22'nd Mar 2021
TORONTO and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody thera
ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer's/Amyloid Field
08:30am, Tuesday, 02'nd Feb 2021
Two positive events in January support PMN310 “best in class” positioning
